Login to Your Account



Symphogen closes $75.4M convertible debt facility

By Michael Fitzhugh
Staff Writer

Thursday, October 22, 2015
Symphogen A/S has closed a €67.5 million (US$75.4 million) convertible debt facility from existing investors that will help the company advance its pipeline, led by Sym004, an antibody mixture currently in a phase IIb study for metastatic colorectal cancer (mCRC) patients with disease resistance or who are refractory to antibody therapies targeting epidermal growth factor receptor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription